AVXL · Anavex Life Sciences Corp.

The sudden termination of long-time CEO Christopher Missling for cause on April 30, 2026, by a Special Committee of independent directors signals serious governance concerns, as the action was based on conduct deemed inconsistent with company policy, with a request for his Board resignation. This leadership shakeup introduces uncertainty for Anavex, a clinical-stage biopharma focused on CNS disorders like Alzheimer's via blarcamesine. The swift appointment of Terrie Kellmeyer as Interim CEO on May 4 leverages her deep internal knowledge from her prior role as SVP Clinical Development (Nov 2023-May 2025) and ongoing Senior Advisor status, plus extensive external experience including regulatory approvals at Intercept, Madrigal, and Acer Therapeutics. Her compensation package—$500k base, 30% bonus target, $150k signing bonus, and 200k options—reflects competitive terms to secure her leadership during transition. No disclosed conflicts enhance credibility. Investors should monitor pipeline progress and the delayed Q1 2026 10-Q filing via Form 12b-25 for financial stability insights.